(Q34515378)

2 August 2017

1 reference

title

Antipsychotic medication: effects on regulation of glucose and lipids (English)

1 reference

2 August 2017

0 references

Kato MM

1

1 reference

2 August 2017

Goodnick PJ

series ordinal

2

1 reference

2 August 2017

language of work or name

English

0 references

publication date

1 October 2001

1 reference

Expert Opinion on Pharmacotherapy

2 August 2017

published in

1 reference

2 August 2017

volume

2

1 reference

2 August 2017

issue

10

1 reference

2 August 2017

page(s)

1571-1582

1 reference

Clozapine, diabetes mellitus, weight gain, and lipid abnormalities: A five-year naturalistic study

2 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2.10.1571

Diabetes mellitus in schizophrenic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2.10.1571

Diabetes trends in the U.S.: 1990-1998.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2.10.1571

Blood Sugar Levels in Patients Treated with Chlorpromazine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2.10.1571

Weight gain: side effect of atypical neuroleptics?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2.10.1571

Mortality and causes of death in schizophrenic patients in Denmark

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2.10.1571

Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2.10.1571

A comparison of quetiapine and chlorpromazine in the treatment of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2.10.1571

Effect of chlorpromazine on blood glucose and plasma insulin in man

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2.10.1571

Olanzapine-induced glucose dysregulation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2.10.1571

Ziprasidone 80 mg/day and 160 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: a 6-week placebo-controlled trial. Ziprasidone Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2.10.1571

Chlorpromazine-induced vanishing bile duct syndrome leading to biliary cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2.10.1571

10.1517/14656566.2.10.1571

21 January 2018

Identifiers

DOI

1 reference

2 August 2017

1 reference